Cargando…

Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection

BACKGROUND: The duration of immunity in SARS-CoV-2 infected people remains unclear. Neutralizing antibody responses are the best available correlate of protection against re-infection. Recent studies estimated that the correlate of 50% protection from re-infection was 20% of the mean convalescent ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Eric HY, Hui, David SC, Tsang, Owen TY, Chan, Wai-Hung, Kwan, Mike YW, Chiu, Susan S, Cheng, Samuel MS, Ko, Ronald LW, Li, John KC, Chaothai, Sara, Tsang, Chi H, Poon, Leo LM, Peiris, Malik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556690/
https://www.ncbi.nlm.nih.gov/pubmed/34746725
http://dx.doi.org/10.1016/j.eclinm.2021.101174
_version_ 1784592219798241280
author Lau, Eric HY
Hui, David SC
Tsang, Owen TY
Chan, Wai-Hung
Kwan, Mike YW
Chiu, Susan S
Cheng, Samuel MS
Ko, Ronald LW
Li, John KC
Chaothai, Sara
Tsang, Chi H
Poon, Leo LM
Peiris, Malik
author_facet Lau, Eric HY
Hui, David SC
Tsang, Owen TY
Chan, Wai-Hung
Kwan, Mike YW
Chiu, Susan S
Cheng, Samuel MS
Ko, Ronald LW
Li, John KC
Chaothai, Sara
Tsang, Chi H
Poon, Leo LM
Peiris, Malik
author_sort Lau, Eric HY
collection PubMed
description BACKGROUND: The duration of immunity in SARS-CoV-2 infected people remains unclear. Neutralizing antibody responses are the best available correlate of protection against re-infection. Recent studies estimated that the correlate of 50% protection from re-infection was 20% of the mean convalescent neutralizing antibody titre. METHODS: We collected sera from a cohort of 124 individuals with RT-PCR confirmed SARS-CoV-2 infections from Prince of Wales Hospital, Princess Margaret Hospital, Queen Elizabeth Hospital and Queen Mary Hospitals of the Hospital Authority of Hong Kong, for periods up to 386 days after symptom onset and tested these for antibody to SARS-CoV-2 using 50% virus plaque reduction neutralization tests (PRNT(50)), surrogate neutralization tests and spike receptor binding domain (RBD) binding antibody. Patients were recruited from 21 January 2020 to 16 February 2021 and follow-up samples were collected until 9th March 2021. FINDINGS: Because the rate of antibody waning slows with time, we fitted lines of decay to 115 sera from 62 patients collected beyond 90 days after symptom onset and estimate that PRNT(50) antibody will remain detectable for around 1,717 days after symptom onset and that levels conferring 50% protection will be maintained for around 990 days post-symptom onset, in symptomatic patients. This would potentially be affected by emerging virus variants. PRNT titres wane faster in children. There was a high level of correlation between PRNT(50) antibody titers and the % of inhibition in surrogate virus neutralization tests. INTERPRETATION: The data suggest that symptomatic COVID-19 disease is followed by relatively long-lived protection from re-infection by antigenically similar viruses. FUNDING: Health and Medical Research Fund, Commissioned research on Novel Coronavirus Disease (COVID-19) (Reference Nos. COVID190126 and COVID1903003) from the Food and Health Bureau and the Theme-based Research Scheme project no. T11–712/19-N, the University Grants Committee of the Hong Kong SAR Government.
format Online
Article
Text
id pubmed-8556690
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-85566902021-11-01 Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection Lau, Eric HY Hui, David SC Tsang, Owen TY Chan, Wai-Hung Kwan, Mike YW Chiu, Susan S Cheng, Samuel MS Ko, Ronald LW Li, John KC Chaothai, Sara Tsang, Chi H Poon, Leo LM Peiris, Malik EClinicalMedicine Research paper BACKGROUND: The duration of immunity in SARS-CoV-2 infected people remains unclear. Neutralizing antibody responses are the best available correlate of protection against re-infection. Recent studies estimated that the correlate of 50% protection from re-infection was 20% of the mean convalescent neutralizing antibody titre. METHODS: We collected sera from a cohort of 124 individuals with RT-PCR confirmed SARS-CoV-2 infections from Prince of Wales Hospital, Princess Margaret Hospital, Queen Elizabeth Hospital and Queen Mary Hospitals of the Hospital Authority of Hong Kong, for periods up to 386 days after symptom onset and tested these for antibody to SARS-CoV-2 using 50% virus plaque reduction neutralization tests (PRNT(50)), surrogate neutralization tests and spike receptor binding domain (RBD) binding antibody. Patients were recruited from 21 January 2020 to 16 February 2021 and follow-up samples were collected until 9th March 2021. FINDINGS: Because the rate of antibody waning slows with time, we fitted lines of decay to 115 sera from 62 patients collected beyond 90 days after symptom onset and estimate that PRNT(50) antibody will remain detectable for around 1,717 days after symptom onset and that levels conferring 50% protection will be maintained for around 990 days post-symptom onset, in symptomatic patients. This would potentially be affected by emerging virus variants. PRNT titres wane faster in children. There was a high level of correlation between PRNT(50) antibody titers and the % of inhibition in surrogate virus neutralization tests. INTERPRETATION: The data suggest that symptomatic COVID-19 disease is followed by relatively long-lived protection from re-infection by antigenically similar viruses. FUNDING: Health and Medical Research Fund, Commissioned research on Novel Coronavirus Disease (COVID-19) (Reference Nos. COVID190126 and COVID1903003) from the Food and Health Bureau and the Theme-based Research Scheme project no. T11–712/19-N, the University Grants Committee of the Hong Kong SAR Government. Elsevier 2021-10-30 /pmc/articles/PMC8556690/ /pubmed/34746725 http://dx.doi.org/10.1016/j.eclinm.2021.101174 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research paper
Lau, Eric HY
Hui, David SC
Tsang, Owen TY
Chan, Wai-Hung
Kwan, Mike YW
Chiu, Susan S
Cheng, Samuel MS
Ko, Ronald LW
Li, John KC
Chaothai, Sara
Tsang, Chi H
Poon, Leo LM
Peiris, Malik
Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
title Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
title_full Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
title_fullStr Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
title_full_unstemmed Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
title_short Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
title_sort long-term persistence of sars-cov-2 neutralizing antibody responses after infection and estimates of the duration of protection
topic Research paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556690/
https://www.ncbi.nlm.nih.gov/pubmed/34746725
http://dx.doi.org/10.1016/j.eclinm.2021.101174
work_keys_str_mv AT lauerichy longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT huidavidsc longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT tsangowenty longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT chanwaihung longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT kwanmikeyw longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT chiususans longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT chengsamuelms longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT koronaldlw longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT lijohnkc longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT chaothaisara longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT tsangchih longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT poonleolm longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection
AT peirismalik longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection